Results 61 to 70 of about 28,421 (276)

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Nature Medicine, 2023
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral
F. Nassiri, V. Patil, L. Yefet, O. Singh, Jeffrey C. Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, M. Daras, T. Cloughesy, H. Colman, P. Kumthekar, Clark C. Chen, R. Aiken, M. Groves, S. Ong, R. Ramakrishna, M. Vogelbaum, S. Khagi, T. Kaley, J. Melear, D. Peereboom, Analiz Rodriguez, M. Yankelevich, S. Nair, V. Puduvalli, Kenneth D. Aldape, A. Gao, Álvaro López-Janeiro, Carlos E. De Andrea, M. M. Alonso, P. Boutros, J. Robbins, W. Mason, A. Sonabend, R. Stupp, J. Fueyo, C. Gomez-Manzano, F. Lang, G. Zadeh   +38 more
semanticscholar   +1 more source

Cytokines in oncolytic virotherapy

Cytokine & Growth Factor Reviews, 2020
Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail ...
Pol, Jonathan, Workenhe, Samuel, Konda, Prathyusha, Gujar, Shashi, Kroemer, Guido   +4 more
openaire   +3 more sources

Oncolytic virotherapy for ovarian cancer [PDF]

Oncolytic Virotherapy, 2012
In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies.
Li, Shoudong, Tong, Jessica, Rahman, Masmudur M., Shepherd, Trevor G., McFadden, Grant   +4 more
openaire   +4 more sources

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]

, 2016
Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa, Curiel, David T, Mathis, J. Michael, O\u27Bryan, Samia M, Rivera, Angel A   +4 more
core   +3 more sources

Exploiting tumor epigenetics to improve oncolytic virotherapy [PDF]

, 2013
Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased ...
Hesham Abdelbary, Jean-Simon Diallo, John C. Bell, Mathieu Lupien, Nicole E. Forbes   +4 more
core   +1 more source

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy

Viruses, 2023
Oncolytic viruses (OVs) have emerged as one of the most promising cancer immunotherapy agents that selectively target and kill cancer cells while sparing normal cells. OVs are from diverse families of viruses and can possess either a DNA or an RNA genome.
J. Enow, Hummad I. Sheikh, Masmudur M. Rahman   +2 more
semanticscholar   +1 more source

Personalizing Oncolytic Virotherapy?

Molecular Therapy, 2007
raditionally, cancer therapies have been based on the empiric discovery of drugs and/or biological agents that act selectively against tumor cells. Recently, however, a generation of rationally discov-ered drugs and agents has been developed that shows encouraging benefi t in treating cancers.
Kaur, Balveen, Chiocca, E Antonio
openaire   +2 more sources

Oncolytic Adenovirus-Induced Autophagy: Tumor-Suppressive Effect and Molecular Basis [PDF]

, 2013
Autophagy is a catabolic process that produces energy through lysosomal degradation of intracellular organelles. Autophagy functions as a cytoprotective factor under physiological conditions such as nutrient deprivation, hypoxia, and interruption of ...
Fujiwara, Toshiyoshi, Kagawa, Shunsuke, Tazawa, Hiroshi   +2 more
core   +1 more source

Oncolytic virotherapy for pancreatic cancer [PDF]

Expert Reviews in Molecular Medicine, 2011
Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas ...
Sonia, Wennier, Shoudong, Li, Grant, McFadden   +2 more
openaire   +2 more sources

Sorting Out Pandora’s Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma [PDF]

, 2014
Oncolytic viral therapies have recently found their way into clinical application for hepatocellular carcinoma (HCC), a disease with limited treatment options and poor prognosis. Adding to the many intrinsic challenges of in vivo oncolytic viral therapy,
Jennifer Altomonte, Oliver Ebert
core   +3 more sources